

FOR HEALTHCARE PROFESSIONALS: IN CASE OF EMERGENCY

I am currently being treated with ENHERTU

Please contact:

Oncologist Name: _____

Oncologist Telephone: _____



ENHERTU[®]

fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

**PATIENTS TREATED WITH THIS MEDICATION
MAY BE AT RISK FOR SERIOUS AND
POTENTIALLY FATAL SIDE EFFECTS, INCLUDING:**

- Interstitial lung disease/pneumonitis
- Neutropenia
- Cardiac events (eg, left ventricular dysfunction)

This is not a complete list of all potential side effects. Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide available at www.ENHERTU.com.



Daiichi-Sankyo

AstraZeneca



ENHERTU® is a registered trademark of Daiichi Sankyo Company, Limited.
© 2022 Daiichi Sankyo, Inc. and AstraZeneca. PP-US-EN-1264 05/22